Process for preparation of Darunavir

1. Darunavir propionate solvate characterized by an X-ray diffraction (XRD) pattern substantially in accordance with FIG. 1 .

2. The darunavir propionate solvate of claim 1 having a chemical purity of greater than about 99.5% as measured by HPLC.

3. The darunavir propionate solvate of claim 1 having less than about 0.1% by HPLC of one or more of its diastereomer impurities,

4. Darunavir propionate solvate of claim 1 having less than about 0.1% by HPLC of one or more of the impurities

5. A method for the preparation of darunavir propionate solvate according to claim 1 comprising:

a) mixing an amount of 1-([[(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yloxy]-carbonyl]oxy)-2,5-pyrrolidinedione of Formula V′, ethyl acetate, and water in a mixing vessel,

b) adding to the reaction mixture of step a) an amount of the compound of Formula II at 25° C. to 30° C.,

c) adding to the reaction mixture of step b) an amount of aqueous potassium carbonate;

d) separating the organic layer thus formed and washing the same with an amount of water;

e) distilling from the organic layer obtained in step d) the ethyl acetate under vacuum to obtain a residue;

f) mixing an amount of propionic acid with the residue obtained from step e) at 25° C. to 30° C. to form the darunavir propionate solvate;

g) precipitating the darunavir propionate solvate from the mixture of step f) and drying the same under reduced pressure to obtain a solid.

6. The method according to claim 5 , further comprising forming a pharmaceutical composition by combining the precipitated solid darunavir propionate solvate or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.